In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Bristol Spins Off Mead Johnson in Stock Swap, Finally Pure Biopharma

Executive Summary

Bristol has finalized its strategy to focus on biopharmaceuticals by swapping its 83% stake in Mead Johnson Nutritionals for BMS shares. The move will not raise cash but the buyback structure of the deal will improve BMS's cash flow and increase earnings per share ahead of its impending Plavix/Avapro patent cliff.

You may also be interested in...

Financings Of The Fortnight: Overseas Cash Holdings Don’t Mean U.S. Biopharma Lacks For Domestic Financial Opportunity

Plus news on recent financing activity by Savara Pharmaceuticals, OvaScience, TetraPhase Pharmaceuticals and Pharmacyclics.

New Ecosystems In Pharma: Maturing Markets Mean New Models Are Needed

Success in the pharmaceutical industry requires new thinking about segmentation of drug markets and new insight into how the opportunity for pharma companies is changing. Oliver Wyman’s ecosystems framework attempts to determine where unmet medical need, innovation, and a strong value proposition for payors reside.

Novartis Eyes Full, $50 billion Alcon Takeover

Novartis on Jan 4 announced it was exercising its option to purchase Nestlé's remaining 52 percent stake in eye-care group Alcon for $28.1 billion. The Swiss Big Pharma will finish up paying almost $50 billion for full control of the group, given its controversial attempt to buy out the minority Alcon shareholders for a further $11.2 billion.

Related Content


Related Companies

Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts